A Message from the President

Dear Colleagues,

As the field of cancer immunotherapy and tumor immunology has grown, so too has the critical need for both global scientific exchange and educational opportunities for a wide array of groups.

Education and scientific exchange is the cornerstone of the Society for Immunotherapy of Cancer.  While the Annual Meeting & Pre-Conference Programs and the Advances in Cancer Immunotherapy™ regional programs are well-known offerings, our society's impact extends to many collaborative education programs as well.

SITC partners with other organizations around the world. These initiatives offer investigators opportunity for scientific exchange and networking, and provide high-quality education for advanced practice providers to learn current treatment strategies involving cancer immunotherapy.

In the past three years alone, SITC has supported more than 60 collaborative programs through connecting SITC member experts as speakers; SITC members' direction on content development; organization and faculty selection of programs; marketing and promotion; financial support of educational programs; and access to SITC resources.

These are some highlights of upcoming collaborations involving SITC:

• 4th Forum on Immunotherapy and Translational Immunology of Cancer (FIT Cancer IV), a collaboration with the Spanish Group for Immuno-Biological Therapies in Cancer (GÉTICA) in Madrid, Spain, March 8-10
• Fifth Immunotherapy of Cancer Conference (ITOC5), a collaboration with the Cancer Drug Development Forum (CDDF) in Berlin, Germany, March 19-21
• Immuno-Oncology Young Investigators' Forum, a mentoring event in collaboration with The University of Texas MD Anderson Cancer Center and Creative Educational Concepts, Inc. (CEC) in Houston, Texas, April 19-22
• Combination Cancer Immunotherapy: Expanding Clinical Success, a SITC session at the American Association of Immunologists (AAI) Annual Meeting in Austin, Texas, May 5  

Ultimately, all of these programs address the goals put forth in the SITC 2016-18 Strategic Plan:

• Collaboration: Cultivate meaningful relationships with key strategic partners
• Engagement: Create a network of cancer immunotherapy stakeholders, providing greater opportunities for engagement and interaction
• Education and Scientific Exchange: Serve as the leading resource for information and education on cancer immunotherapy
• Global Impact: Advance the science and application of cancer immunotherapy world-wide
• Science and Research: Challenge the thinking and seek the best research in the exploration and development of tumor immunology and cancer immunotherapy

We're looking forward to an additional 20+ educational programs in 2018. Our society has flourished because of our outstanding members. Thank you all for sharing your expertise and experience, dedication and leadership, which have allowed SITC to make strides towards making the word "cure" a reality for patients everywhere.

Best wishes,

SITC President

Science, Research & Publications

CALL FOR PAPERS: SUBMISSION DEADLINE FRIDAY, MARCH 2
For a limited time, JITC is offering additional promotional coverage for papers published in the upcoming three series: Emerging Immunotherapeutic Agents, New Regulatory Approvals in Cancer Immunotherapy, and Challenges in Clinical Management. Coverage includes dedicated series emails to SITC's database of cancer immunotherapy professionals, social media promotion, an announcement on SITC CONNECT, and more 

Full details and submission guidelines may be found here

NEW CANCER IMMUNOTHERAPY GUIDELINES COMING SOON! 

SITC's Cancer Immunotherapy Guidelines are a series of consensus recommendations providing practical clinical guidance on when and how to use immunotherapy in patients with specific types of cancer. Developed by experts in the field, the Guidelines provide practicing oncologists with guidance on patient selection, sequencing or combination of therapies, and toxicity management.

Guidelines are currently available in JITC for the following cancers:

• Renal cell carcinoma
• Prostate carcinoma
• Bladder carcinoma
• Hematologic malignancies

Watch for the following new or updated guidelines later this year:

• Cutaneous melanoma
• Non-small cell lung carcinoma (NSCLC)
  

Education

UPCOMING COLLABORATIVE EDUCATION PROGRAMS 

Review SITC's Events Calendar here to learn about upcoming collaborative education programs, such as the FIT Cancer IV, ITOC5 and Young Investigators' Forum mentioned in Dr. Butterfield's President's Message. Through these programs, SITC brings cancer immunotherapy expertise around the globe.

LIVE WEBCAST OF SITC INTRODUCTORY CANCER IMMUNOTHERAPY PROGRAM –
MARCH 3

SITC will offer a webcast of our Advances in Cancer Immunotherapy™ introductory educational program 8 a.m - 2 p.m. on March 3. Register for this program or with your community oncologists, nurses, pharmacists and other colleagues who should attend.

In-person SITC Advances in Cancer Immunotherapy™ programs will be held in Dallas, Texas; Miami, Florida; and
Buffalo, New York in the coming weeks. Encourage your colleagues residing in these regions to attend this program in person. Whether you attend the program virtually through the webcast or join in person, you will earn CME, CNE and CPE credits and hear from experts in the field on:

• Latest developments in immune-related adverse event management
• Clinical applications of immunotherapy for various disease states
• Strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a hospital setting

REGISTER NOW FOR SITC CANCER IMMUNE RESPONSIVENESS AND BIOMARKERS WORKSHOP 

Registration is now open for SITC's spring workshops:

• Cancer Immune Responsiveness – May 14-15, 2018 in San Francisco, CA
• Immuno-Oncology Biomarkers: State of the Art – May 16-17, 2018 in San Francisco, CA

NEW PATIENT RESOURCES AVAILABLE

Share these new, FREE resources with your patients: